RSS Subscribe to our Nanotechnology Business News feed

Biolaxy Secures IND Approval for Nanoparticle Oral Insulin Delivery

Shanghai Biolaxy announced the Chinese State Food and Drug Administration (SFDA) has approved the investigational new drug application (IND) for its oral insulin project (Nodlin), an innovative insulin formulation to treat diabetes. This IND approval allows Biolaxy to initiate its first phase I clinical study.

Nov 24th, 2009

Read more